-

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcom’s global operations and quality teams, driving greater alignment, speed, and accountability across the company as it executes on its vision for growth and commitment to operational excellence.

Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. Throughout his tenure at Dexcom, Mr. Sylvain has built a strong finance leadership team and guided the company’s journey of growth and margin expansion. He has also demonstrated the ability to align and execute cross-functionally, bringing the combination of strategic judgment, operational discipline, and commitment to customers that are key for Dexcom’s next phase of growth and scale.

“Jereme is an exceptional leader and a valued strategic partner across Dexcom,” said Jake Leach, President and CEO. “His deep understanding of our business, operational discipline and customer focus make him the right leader for this expanded role. I am confident that Jereme will help us scale more effectively as we advance our goal to empower millions more people to take control of health.”

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit Dexcom.com.

Category: IR

Contacts

Media Contact
Nadia Conard
mediarelations@dexcom.com

Investor Contact
Sean Christensen
investor-relations@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Summary
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Release Versions

Contacts

Media Contact
Nadia Conard
mediarelations@dexcom.com

Investor Contact
Sean Christensen
investor-relations@dexcom.com

More News From DexCom, Inc.

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program’s largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l...

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo...
Back to Newsroom